<DOC>
	<DOCNO>NCT02981745</DOCNO>
	<brief_summary>This phase I study BTK inhibitor CT-1530 patient relapse refractory B cell non-Hodgkin lymphoma ( B-NHL ) , chronic lymphocytic leukemia ( CLL ) Waldenstrom 's macroglobulinemia ( WM ) . The purpose study determine MTD/RP2D CT-1530 , evaluate safety tolerability monotherapy subject relapse refractory B cell non-Hodgkin lymphoma ( B-NHL ) , chronic lymphocytic leukemia ( CLL ) Waldenstrom 's macroglobulinemia ( WM ) .</brief_summary>
	<brief_title>Study Safety , Efficacy Pharmacokinetics CT-1530 Patients With Relapsed Refractory B Cell Non-Hodgkin Lymphoma , Chronic Lymphocytic Leukemia , Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Confirmed diagnosis B cell NonHodgkin Lymphoma ( accord World Health Organization [ WHO ] classification ) include Chronic Lymphocytic Leukemia/Small cell Lymphocytic Leukemia ( International Workshop ) , Waldenstrom 's Macroglobulinemia ( Second International Workshop ) . Have fail ≥1 previous treatment BNHL/CLL/WM , relapse refractory disease follow last prior treatment . Eastern Cooperative Oncology Group performance status ≤ 1 life expectancy least 3 month . Measurable disease per RECIST v1.1 Availability tumor sample Adequate hematologic function , define neutrophil ≥ 1.0 x 10^9/L platelet ≥ 50 x 10^9/L ; patient neutrophils &lt; 1.0 x 10^9/L due marrow infiltration allow receive growth factor bring pretreatment neutrophil ≥ 1.0 x 10^9/L . Adequate renal function , define creatinine clearance ≥ 50 ml/min ( estimate CockcroftGault equation measure nuclear medicine scan 24 hour urine collection ) . Adequate liver function , define AST ALT ≤ 3 x ULN , bilirubin ≤ 1.5 x ULN ( unless document Gilbert 's syndrome ) . Prior allogeneic bone marrow transplant Autologous stem cell transplant within 3 month screen Active central nervous system involvement Subjects autoimmune hemolytic anemia immune thrombocytopenia Prior treatment Btk inhibitor Active uncontrolled infection History malabsorption Uncontrolled illness , i.e cardiac , endocrine , respiratory , etc . History myocardial infarction , acute coronary syndrome , coronary angioplasty and/or stenting previous 6 month History another currently active cancer History major surgery within 4 week minor surgery within 1 week Other medical psychiatric illness organ dysfunction HIV positive Positive Hepatitis B surface antigen Hepatitis Cvirus Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>